Evaluation of the Efficacy of Diafert in Predicting Embryos' Potential to Develop to the Blastocyst Stage

NCT ID: NCT02788617

Last Updated: 2017-07-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-06-24

Study Completion Date

2017-04-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective study will evaluate the efficacy of Diafert as an adjunct to morphological assessment in predicting embryos' potential to develop to the blastocyst stage on Day 5.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infertility

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Non treatment group

This is a non-interventional study in which embryo selection is performed according to standard of care. The Diafert output, the granulocyte colony-stimulating factor (G-CSF) concentration in follicular fluid (FF), will be recorded but will not be used in patient management, ie, values will not be used for embryo selection in the assisted reproduction procedure.

Diafert

Intervention Type DEVICE

The Diafert output, the G-CSF concentration in FF, will be recorded but will not be used in patient management.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diafert

The Diafert output, the G-CSF concentration in FF, will be recorded but will not be used in patient management.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provide written informed consent before initiation of any study procedures
* Be a female outpatient, ≥ 18 years of age at the time of informed consent
* Have at minimum 10 mature egg follicles as of the last transvaginal ultrasound following hormonal stimulation
* Eligible to allow embryos to develop through day 5 before implantation or freezing

Exclusion Criteria

* Presence of ovarian endometriotic cyst
* Presence or history of diagnosed severe endometriosis (i.e. stage IV the revised American Fertility Society classification for endometriosis).
* Need for pre-implantation genetic diagnosis/screening of embryos
* Use of time-lapse embryo imaging
* Employee or immediate relative of an employee of Forest Research Institute, Inc., any of its affiliates or partners, or the study center
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Forest Laboratories

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Fabian Somers, PhD

Role: STUDY_DIRECTOR

Allergan

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Huntington Reproductive Center

Encino, California, United States

Site Status

Women's Medical Research Group

Clearwater, Florida, United States

Site Status

InVia Fertility Specialists

Hoffman Estates, Illinois, United States

Site Status

Institute for Reproductive Health

Cincinnati, Ohio, United States

Site Status

Main Line Fertility Center

Bryn Mawr, Pennsylvania, United States

Site Status

Dallas - Fort Worth Fertility Associates

Dallas, Texas, United States

Site Status

Houston Fertility Institute

Houston, Texas, United States

Site Status

Utah Fertiity Center

Pleasant Grove, Utah, United States

Site Status

Reproductive Care Center

Sandy City, Utah, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DFT-MD-05

Identifier Type: -

Identifier Source: org_study_id